table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 all comers
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose

1 studies excluded by filtering options 3

5633 ARI-RAF (Della-Torre), 2020 1130not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons